Hello everyone, I’m not sure if this has been asked before but as with anything relating symptoms, many of us are unique is some ways. I just hope someone who has had similar experiences to me can help.

I’m a 33 year old male.

So, after doing keto for 1 month in January in order to try and lower my blood sugar, I started having symptoms of tenesmus and loose stools. I brushed it off for 2 weeks then decided to go to a gastroenterologist.

They did CT scan with contrast, stool test, and blood test. CT came back normal, stool test showed no occult blood or inflammation. Blood test did showed inflammatory markers though. My doctor told me my issue was anxiety that I should speak to a psychologist. He did not officially diagnosed me with IBS but that’s the universal diagnosis I suppose. My symptoms did not improved and I got discouraged from visiting the doctor again because I went 4 times and never came out with a solution.

I ordered a GI map test in March and the results showed no detectable Akkermansia and 3 opportunistic bacteria were high. I figured ok this is probably my solution, I ordered Pendulum Akkermansia, took it for 2 weeks but my tenesmus got worse, I stopped taking it but now I’m dealing with horrible burning in the sigimoid and rectum and last night the burning sensation went up my entire GI tract, and then on random parts of my skin.

Has anyone taken that supplement and had similar experiences?

Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

• MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo
• Improvements observed across key symptoms, including nausea, early satiety, post-prandial fullness and upper abdominal pain
• Favorable safety and tolerability profiles
• Late-breaking oral presentation delivered at Digestive Disease Week (DDW) 2026 in Chicago, IL.

 

Freiburg, Germany and Roscrea, Ireland – May 4, 2026 - Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis.

The double-blind, multicenter, 12-week study enrolled 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis symptoms and objective evidence of delayed gastric emptying. Eligible patients received either 10 mg, 20 mg, 40 mg naronapride, or placebo, administered orally three times a day (TID) for 12 weeks. 

MOVE-IT met the primary endpoint, demonstrating statistically significant improvement versus placebo in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Core Symptom Score in the 20 mg TID (p=0.0046) and 40 mg TID (p=0.0156) groups. The ANMS GCSI-DD is a content-validated, patient-reported outcome instrument that assesses the five cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness and upper abdominal pain.

As title, is there any with credible evidence that isn't entirely sponsored?

Highlights

• IBS associated with immune-mediated peripheral neuropathies
• Risk increase observed across GBS-related outcomes
• No association found with classic GBS
• Supports gut–immune–neural interaction

Abstract

Background

Irritable bowel syndrome (IBS) is recognized as a systemic disorder involving gut–brain–immune axis dysregulation, but its long-term association with immune-mediated peripheral neuropathies, including Guillain–Barré syndrome (GBS), is unclear.

Methods

We conducted a nationwide retrospective cohort study using the Korean National Health Insurance database, including approximately 2 million adults from 2012 to 2023. Incident IBS cases were identified after a 3-year washout period and matched 1:2 with controls by age, sex, and health examination year. Primary outcomes were GBS immune-mediated peripheral neuropathies and GBS and related immune-mediated peripheral neuropathies defined by ICD-10 codes; classic GBS was a secondary outcome. Cox proportional hazards models were applied.

Results

Among 141,781 patients with IBS and matched controls, IBS was associated with increased risk of the primary outcomes (incidence rate ratio, 1.57; 95% CI, 1.48–1.66). In fully adjusted models, IBS remained associated with GBS immune-mediated peripheral neuropathies (adjusted HR, 1.58; 95% CI, 1.44–1.73) and GBS and related immune-mediated peripheral neuropathies (adjusted HR, 1.50; 95% CI, 1.37–1.65), but not with classic GBS (adjusted HR, 1.25; 95% CI, 0.55–2.87).

Conclusions

IBS was associated with increased long-term risk of GBS spectrum immune-mediated peripheral neuropathies, suggesting a potential association with systemic immune-related condition.

Anyone on it? It calms the inflammation and intestines.

May 5, 2026

• Topline results expected Q3 2026

WATERTOWN, Mass. – May 5, 2026 – Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that its Phase 2b ASPIRE trial evaluating taplucainium for the treatment of refractory or unexplained chronic cough (rCC/uCC) is fully enrolled.

“Fully enrolling the Phase 2b ASPIRE trial represents a major milestone on the path to delivering a transformative new therapy for patients with chronic cough,” said Matthew Frankel, M.D., MBA, Chief Medical Officer of Nocion Therapeutics. “Taplucainium’s differentiated mechanism has the potential to deliver fast-acting and long-lasting relief by addressing the underlying drivers of chronic cough. The rapid pace of enrollment underscores the strong demand among clinicians and patients for a safe and effective treatment for this undertreated, debilitating condition. With the Phase 2b trial now fully enrolled, we are on track to report topline data in Q3 2026 to support a potential registrational program for taplucainium.”

ASPIRE is a Phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of taplucainium inhalation powder once daily in adults with rCC/uCC. The study has reached its target enrollment of 240 patients across more than 100 sites in the U.S., Canada, U.K. and EU. Patients were randomized into one of four groups either receiving taplucainium 1 mg, 3 mg, 6 mg, or placebo over 1 month of treatment. The primary endpoint is the change in 24-hour coughs per hour from baseline to end of treatment (as measured by VitaloJAK® Cough Counts). Key secondary endpoints include change in awake coughs, cough severity, and urge to cough.

Additional information about the ongoing ASPIRE study can be found at clinicaltrials.gov (Identifier: NCT06504446).

In a session at DDW 2026, Professor Nicholas Talley traced a historical evolution of these conditions, stating that some of them remain, in clinical practice, as they were in 1910 (citing the case of functional dyspepsia).

Source: https://x.com/PaulMoayyedi/status/2051332009482498284/photo/1

Changing the terminology used to describe these conditions is fundamental, but can only occur if accompanied by pathophysiological investigation and targeted treatments.

Today, there are new testable models proposed, but Rome V ignores them in its introductory chapter and theoretical definition.

Source: https://x.com/GI_NutritionFdn/status/2051326263369842897

Furthermore, Talley criticized the fundamentalism imposed by diagnostic criteria such as Rome V.

Source: https://x.com/PaulMoayyedi/status/2051329214201078167

ABSTRACT

Background

Gut-directed hypnotherapy is an effective treatment for patients with irritable bowel syndrome (IBS). Group delivery and nurse-led hypnotherapy can increase availability. Online treatment shows promising results, but this has not been tested in a group format.

Aims

To investigate the acceptability and efficacy of nurse-led, online group hypnotherapy in patients with IBS.

Methods

Patients received eight sessions of gut-directed hypnotherapy in groups via live video conferencing. IBS symptoms were assessed at baseline, mid-treatment, after treatment, and at follow-up. Patients who reported an IBS-SSS reduction of ≥ 50 points were considered responders. Extracolonic symptoms, psychological symptoms, and quality of life were assessed, as well as usability and treatment satisfaction. The study results were compared to previous assessments of group hypnotherapy delivered on-site. After hypnotherapy, patients were asked which treatment modality (online or on-site) they would prefer.

Results

We included 51 patients. IBS severity was reduced after hypnotherapy (median IBS-SSS: 304 (225–385) vs. 225 (172–312), p < 0.001), and 27 patients (53%) were responders. These results are comparable to on-site group hypnotherapy outcomes; IBS-SSS: 310 (232–368) versus 230 (151–330), p < 0.001, responders: 55%. Symptom reduction was sustained at six-month follow-up. Quality of life, extracolonic, and psychological symptoms also improved. The patient ratings of the usability of the video call platform and treatment satisfaction were high.

Conclusions and Inferences

Nurse-led, gut-directed group hypnotherapy delivered online is acceptable, often preferred by patients, and has comparable efficacy to in-person group hypnotherapy. By combining group and online treatment, hypnotherapy can be made more accessible for patients.

Key Points

• Gut-directed hypnotherapy is a brain–gut behavioral therapy that is effective for patients with irritable bowel syndrome, but access to treatment is limited.
• In this pilot study, we tested to give nurse-led group hypnotherapy using a digital video platform to increase accessibility further.
• Study outcomes show that the treatment modality is feasible, efficacious, and acceptable for patients.